论文部分内容阅读
疟疾是全球广泛流行的寄生虫病。恶性疟原虫株对常规抗疟药多已产生耐药性。青蒿素类现作为一线抗疟药用于临床。从现有文献着手,本文综述了恶性疟原虫对抗疟药的抗性现状,比较了恶性疟原虫对青蒿素类药物与喹啉类药物的敏感性,提示青蒿素类药物目前作为首选药应用于临床的优点。疟疾治疗的主要困难是耐药性产生,而联合用药是避免或延缓耐药性产生,提高疗效的有效手段,因此本文还综述了以青蒿素类药物为基础的抗疟药联合用药现状及初步比较,提示以青蒿素为基础的联合用药方案有其他可能的组合。
Malaria is a pandemic that is widespread worldwide. Plasmodium falciparum strains have developed resistance to conventional antimalarial drugs. Artemisinin is now used as a first-line antimalarial drug for clinical use. Starting from the existing literature, this article reviews the current status of the resistance of Plasmodium falciparum to anti-malarial drugs and compares the sensitivity of Plasmodium falciparum to artemisinin-type drugs and quinoline drugs, suggesting that artemisinin-based drugs are currently the preferred drugs. Applied to clinical advantages. The main difficulty in the treatment of malaria is the emergence of drug resistance, and combined use of drugs is an effective means to avoid or delay the development of drug resistance and improve efficacy. Therefore, the current status of the combination of antimalarial drugs based on artemisinin-based drugs is also reviewed. Preliminary comparisons suggest that there are other possible combinations of artemisinin-based combination regimens.